Medline's Fire and Tariffs Mask a Growth Engine That's Still Firing at 11%

The market is pricing Medline as a margin-collapse story. The stock fell 15.7% today after the company lowered its full-year adjusted EBITDA guidance to $3.3 billion–$3.4 billion from $3.5 billion–$3.6 billion. That's the headline. It's also the wrong frame.

Medline raised its organic sales outlook to 9.0% to 10.0%, up from 8.5%–9.5% just three months ago, because its revenue engine is still pulling. The profit miss is dominated by a warehouse fire, a one-time quality remediation program, and temporary tariff accounting noise. Strip those out, and the operating setup underneath is materially better than the tape suggests.

Here's the factual spine. Q2 net sales grew 11.6% to $7.7 billion. Organic sales rose 11.5%. Adjusted EBITDA - earnings before interest, taxes, depreciation, and amortization, a rough cash-earnings proxy - increased 13.4% to $1.06 billion. That was enough to push the stock down 15% because GAAP net income fell 58.3% to $139 million. The income decline was driven by a $336 million loss from a fire at the Tracy, California distribution center, recorded before expected insurance recoveries. Management expects another $50 million to $100 million of fire-related costs in the second half.

The IEEPA (International Emergency Economic Powers Act) tariff accounting adds another layer of confusion. The Supreme Court struck down those tariffs in February. Medline received $332 million in tariff refunds, reduced its cost of goods sold by that amount, and repaid $89 million to customers who had passed the tariff cost through. The net $243 million benefit flowed through both GAAP income and adjusted EBITDA. It's real cash, but it's a one-time event that makes year-over-year comparisons ugly.

The growth story doesn't depend on any of that. Medline has secured more than 65% of its annual new-customer-signing goal - measured by estimated annual contract value - in the first half. Supply Chain Solutions, the recurring-revenue side of the business that locks hospitals into Medline's product ecosystem, grew 16%. The company is the largest provider of medical-surgical products and supply chain solutions in the U.S., and the customer pipeline ahead of it is still full.

Free cash flow is the anchor that matters here. In the first six months, operating cash flow was $1.127 billion, up 28% from the prior year. After $207 million of capital spending - primarily distribution-center automation and kitting manufacturing investments - free cash flow came in at $920 million, up 37% year over year. That's the hard number. The market is fixated on the fire and the EBITDA cut while the cash conversion machine accelerated.

Cash and cash equivalents sit at $2.33 billion. Net debt is $10.1 billion, giving a net leverage ratio of 2.9 times adjusted EBITDA - right at the company's long-term target of below three. With a TTM free cash flow of roughly $1 billion, that leverage is manageable even if margins stay under pressure through the rest of the year.

The lowered EBITDA guidance is the real question. Management pointed to four headwinds: Middle East conflict-related inflation, the Tracy fire, quality remediation spending (including delayed reintroduction of CHG wipes), and softness in the retail channel. Two of those - the fire and quality remediation - are temporary. The retail channel is cyclical. The geopolitical inflation is uncertain but not structural to a business that sells medical disposables hospitals need regardless of the headline environment.

The valuation tells you what the market has done with this information. The enterprise value of $56.9 billion implies roughly 17.0 times the updated mid-point EBITDA guidance of $3.35 billion. Twelve months ago, Medline traded at multiples well above that level while growing far slower than the current 11% organic pace. A company growing 9%–10% organically at 17.0 times forward EBITDA is not being punished for risk; it's being punished for noise.

AInvest's aggregate signal still labels Medline a Buy, with a composite analysis rating of 4.02. That's the old consensus view, and it hasn't shifted despite the 21% decline over the past four months. The analyst base hasn't re-priced the thesis yet, which means the expectations reset is deeper on the tape than it is on the Street.

The setup for the next 12 months is this: if organic sales hold near 9%–10%, fire and quality costs fade behind the growth, and free cash flow stays above $900 million annualized, the business will look harder to dismiss at current levels. The stock is trading at roughly 70% of its 52-week high, down from $50.88. That kind of compression in a business with intact growth and accelerating cash flow is the exact kind of entry this framework looks for - when the market has become skeptical while the numbers keep improving underneath.

A simple forward multiple bridge supports the case. If EBITDA comes in at the mid-point of $3.35 billion and the stock re-rates to 18 times - well below where it traded before the selloff, and in line with med-surg peers that grow at a similar pace - that implies an enterprise value of roughly $60 billion. Subtract net debt of $10.1 billion and you get $50 billion in equity value. Twelve-month timeframe. That's not a DCF exercise. It's a basic multiple on a known earnings base growing double digits.

What could break the thesis. Supply Chain Solutions margins fell from 5.6% to 4.9% in Q2 despite 16% revenue growth. If that segment continues to lose profitability as Medline undercuts competitors to win hospital contracts, the growth story becomes marginally positive at best. Quality remediation could also prove more persistent than management suggests, particularly if the CHG wipe issue reveals broader manufacturing weaknesses. And if Middle East-related input costs don't ease in the second half, the EBITDA recovery path stretches further out.

The tripwire is clear: if Supply Chain Solutions margins fall below 4% in H2 while revenue growth stays above 12%, the growth model is burning cash to chase volume, and the rerating thesis breaks. Cut without ego.

Otherwise, the market is still pricing the fire and the tariff accounting while the revenue engine and cash flow machine are running. The next 12 months look better than the tape suggests. That's the setup.